Real-World Data from Over 6,100 Patients Corroborates Significant Pain Reduction from Prior Prospective Studies for Patients Treated with SPRINT® PNS
May 17, 2023 10:16 ET
|
SPR Therapeutics, Inc.
CLEVELAND, May 17, 2023 (GLOBE NEWSWIRE) -- SPR® Therapeutics announced the publication of a comprehensive real-world retrospective data analysis of over 6,100 patients demonstrating significant...
SPR Therapeutics’ 14-Month Data from Multicenter Low Back Pain Trial Demonstrates Significant, Durable Impacts on Pain Intensity, Disability, and Pain Interference
March 16, 2023 08:00 ET
|
SPR Therapeutics, Inc.
CLEVELAND, March 16, 2023 (GLOBE NEWSWIRE) -- SPR Therapeutics, a private medical device company focused on treating pain and improving the quality of life for patients suffering from acute or...
SPR Therapeutics Receives 510(k) Clearance of Technological Advancements and an Expanded Intended Patient Population for the SPRINT® PNS System
February 03, 2023 15:32 ET
|
SPR Therapeutics, Inc.
CLEVELAND, Feb. 03, 2023 (GLOBE NEWSWIRE) -- SPR Therapeutics, a private medical device company focused on treating pain and improving the quality of life for patients managing acute or chronic...
Real-World Retrospective Review of Axial Neck Pain Relief Following Peripheral Nerve Stimulation of Cervical Medial Branch Nerves
September 21, 2022 15:02 ET
|
SPR Therapeutics, Inc.
- Data presented at Pacific Spine Pain Society annual meeting - CLEVELAND, Sept. 21, 2022 (GLOBE NEWSWIRE) -- SPR Therapeutics shared data on the use of peripheral nerve stimulation (PNS) to...
FDA Clearance of an Expanded Indication for the SPRINT® PNS System Now Enables Treatment in Areas of the Head, Neck, and Torso
October 19, 2021 12:22 ET
|
SPR Therapeutics, Inc.
CLEVELAND, Ohio, Oct. 19, 2021 (GLOBE NEWSWIRE) -- SPR Therapeutics® has obtained clearance from the U.S. Food and Drug Administration (FDA) of a broader indication for use for its SPRINT Peripheral...
SPR Therapeutics Closes $37 Million Growth Equity Financing for Commercial Expansion of its SPRINT® PNS System
October 18, 2021 09:17 ET
|
SPR Therapeutics, Inc.
CLEVELAND, Oct. 18, 2021 (GLOBE NEWSWIRE) -- SPR Therapeutics, a private medical device company focused on providing patients with pain relief without opioids or surgery, announced today it has...
Researchers Unveil a New Theory Explaining Long-term Pain Relief
March 15, 2021 09:30 ET
|
SPR Therapeutics, Inc.
CLEVELAND, March 15, 2021 (GLOBE NEWSWIRE) -- A novel theory recently published in the Journal of Pain Research proposes mechanisms by which a 60-day treatment using percutaneous peripheral nerve...
SPRINT® PNS System Demonstrates the Important Role of the Multifidus in Treating Recurrent Low Back Pain Following RFA
March 02, 2021 10:45 ET
|
SPR Therapeutics, Inc.
CLEVELAND, March 02, 2021 (GLOBE NEWSWIRE) -- SPR Therapeutics, Inc., a leader in neurostimulation technology for pain management, announced publication of clinical data evaluating the impact of...
Study of Sprint Peripheral Nerve Stimulation System Demonstrates 12 Months of Low Back Pain Relief Following 60-Day Treatment
January 21, 2020 08:55 ET
|
SPR Therapeutics, Inc.
CLEVELAND, Jan. 21, 2020 (GLOBE NEWSWIRE) -- SPR Therapeutics, Inc., a leader in neurostimulation technology for pain management, today announced publication of a prospective case series regarding...
SPR Therapeutics Announces 1000th Sprint PNS Procedure
December 04, 2019 08:30 ET
|
SPR Therapeutics, Inc.
CLEVELAND, Dec. 04, 2019 (GLOBE NEWSWIRE) -- SPR Therapeutics, Inc., a leader in neurostimulation technology for pain management, announced today the successful commercial placement of its 1000th...